LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

NCT02098161 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
Primary Myelofibrosis
Secondary Myelofibrosis

Interventions

OTHER: Laboratory Biomarker Analysis
OTHER: Questionnaire Administration
DRUG: Smac Mimetic LCL161

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]